Journal
FUTURE ONCOLOGY
Volume 15, Issue 17, Pages 1975-1987Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0883
Keywords
BRCA-mutated ovarian cancer; BRCA mutations; maintenance treatment; ovarian cancer; PARP inhibitors; poly (ADP-ribose) polymerase inhibitors; veliparib
Categories
Ask authors/readers for more resources
The role of poly ADP ribose polymerase inhibitors in ovarian cancer is rapidly evolving. Three different poly ADP ribose polymerase inhibitors (olaparib, niraparib and rucaparib) have been already approved as maintenance after response to platinum-based chemotherapy; two of them (olaparib and rucaparib) also as single agents. Veliparib, a novel PARPI, showed promising results in preclinical and early clinical settings. The aim of this review is to discuss veliparib's mechanisms of action, to provide a clinical update on its safety and activity in ovarian cancer, and to highlight future perspectives for its optimal use. Veliparib favorable toxicity profile encourages its use either as monotherapy or in combination. Its peculiar neuroprotective and radio-sensitizing effect warrant further investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available